MedSpeed to Provide Transportation Logistics to Sequenom Center for Molecular Medicine
Leading Healthcare Logistics Company Partners with Laboratory Science Innovator
Elmhurst, IL, October 28, 2009 --(PR.com)-- MedSpeed LLC, a leading provider of integrated transportation services to the healthcare industry, announced today that it has partnered with Sequenom Center for Molecular Medicine, LLC (Sequenom CMM) to manage and execute its national transportation services. Headquartered in Grand Rapids, Michigan, Sequenom CMM is a next-generation CLIA (Clinical Laboratory Improvement Amendments, 1988) molecular diagnostic laboratory and a wholly-owned subsidiary of Sequenom, Inc. (Nasdaq: SQNM).
Faced with the demands of launching its service offering on a national scale, Sequenom CMM chose to work with MedSpeed to give it turnkey access to a comprehensive, customer centric logistics operation. “Partnering with MedSpeed immediately provides our laboratory with a flexible, top quality service offering at an affordable cost,” said Howard Slutsky, senior director of operations at Sequenom CMM. “And, because MedSpeed’s operation is seamlessly scalable, we can focus on building our business knowing that our logistics function will accommodate our growth.”
To support Sequenom CMM, MedSpeed bolstered its corporate-based dispatch and analytical capacities as well as expanded its operational reach. Working collaboratively with Sequenom CMM, MedSpeed tailored these and other elements of its service solution to match Sequenom CMM’s current and future needs.
“We are delighted to be working with Sequenom CMM,” said Jake Crampton, CEO, MedSpeed. “Sequenom CMM is not only a thought and technology leader in life sciences, its operational needs for commercialization also support MedSpeed’s establishment of a national footprint.”
About MedSpeed:
MedSpeed is an innovative provider of transportation services exclusively to the healthcare industry. MedSpeed designs and executes centralized transportation outsourcing solutions for integrated healthcare delivery networks, independent clinical laboratories, blood banks, and institutional pharmacies. ISO certified and guided by the principles of Lean Six Sigma, MedSpeed helps its healthcare customers improve and standardize service, reduce costs and focus on core goals. For more information, visit www.medspeed.com.
About Sequenom Center for Molecular Medicine
In 2008, Sequenom acquired a CAP accredited and CLIA-certified molecular diagnostic laboratory located in Grand Rapids, Mich. and named it the Sequenom Center for Molecular Medicine. Through this laboratory, the company plans to develop and commercialize a full range of cutting-edge diagnostic tests intended for physicians and that focus on women's health. In addition to the recently launched SensiGene Cystic Fibrosis Carrier Screening test, Sequenom CMM is also developing noninvasive prenatal tests using a technology that derives fetal information from a maternal blood sample; the planned menu includes tests for fetal RHD genotyping, Fetal(xy) (fetal sex determination), trisomy 21, and others. For more information please visit http://www.scmmlab.com.
Sequenom Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom CMM building its business, its growth, the Company’s plans through Sequenom CMM to develop and commercialize a full range of cutting-edge diagnostic tests including noninvasive prenatal tests and a planned menu of tests including tests for fetal RHD genotyping, Fetalxy fetal sex determination, trisomy 21, and others, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s ability to develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal and other diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company’s ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals and other risks detailed from time to time in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
###
Faced with the demands of launching its service offering on a national scale, Sequenom CMM chose to work with MedSpeed to give it turnkey access to a comprehensive, customer centric logistics operation. “Partnering with MedSpeed immediately provides our laboratory with a flexible, top quality service offering at an affordable cost,” said Howard Slutsky, senior director of operations at Sequenom CMM. “And, because MedSpeed’s operation is seamlessly scalable, we can focus on building our business knowing that our logistics function will accommodate our growth.”
To support Sequenom CMM, MedSpeed bolstered its corporate-based dispatch and analytical capacities as well as expanded its operational reach. Working collaboratively with Sequenom CMM, MedSpeed tailored these and other elements of its service solution to match Sequenom CMM’s current and future needs.
“We are delighted to be working with Sequenom CMM,” said Jake Crampton, CEO, MedSpeed. “Sequenom CMM is not only a thought and technology leader in life sciences, its operational needs for commercialization also support MedSpeed’s establishment of a national footprint.”
About MedSpeed:
MedSpeed is an innovative provider of transportation services exclusively to the healthcare industry. MedSpeed designs and executes centralized transportation outsourcing solutions for integrated healthcare delivery networks, independent clinical laboratories, blood banks, and institutional pharmacies. ISO certified and guided by the principles of Lean Six Sigma, MedSpeed helps its healthcare customers improve and standardize service, reduce costs and focus on core goals. For more information, visit www.medspeed.com.
About Sequenom Center for Molecular Medicine
In 2008, Sequenom acquired a CAP accredited and CLIA-certified molecular diagnostic laboratory located in Grand Rapids, Mich. and named it the Sequenom Center for Molecular Medicine. Through this laboratory, the company plans to develop and commercialize a full range of cutting-edge diagnostic tests intended for physicians and that focus on women's health. In addition to the recently launched SensiGene Cystic Fibrosis Carrier Screening test, Sequenom CMM is also developing noninvasive prenatal tests using a technology that derives fetal information from a maternal blood sample; the planned menu includes tests for fetal RHD genotyping, Fetal(xy) (fetal sex determination), trisomy 21, and others. For more information please visit http://www.scmmlab.com.
Sequenom Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom CMM building its business, its growth, the Company’s plans through Sequenom CMM to develop and commercialize a full range of cutting-edge diagnostic tests including noninvasive prenatal tests and a planned menu of tests including tests for fetal RHD genotyping, Fetalxy fetal sex determination, trisomy 21, and others, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company’s ability to develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal and other diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company’s ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals and other risks detailed from time to time in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
###
Contact
MedSpeed, LLC
Lynn Jensen
(630) 335-9892
medspeed.com
Lynn Jensen
(630) 335-9892
medspeed.com
Contact
Categories